Abstract. Nerve root metastasis of cancer has been rarely reported. We herein report the case of a cervical cancer patient with metastasis to peripheral nerve roots. A 47 year-old woman with cervical squamous cell carcinoma was admitted to our department with a 6-month history of right leg pain, and was investigated for cancer recurrence. Magnetic resonance imaging revealed lymph node metastasis near the right iliac blood vessels; the patient was then treated with chemotherapy with paclitaxel and carboplatin. However, the pain worsened and the muscle strength of her right leg decreased. On positron emission tomography̸computed tomography scans, the sacral plexus L5̸S1 and L4̸5 nerves appeared thickened, suggesting nerve metastases. Intensity-modulated radiation therapy was applied, with notable clinical benefit. However, the patient succumbed to the disease 3 months later.
Introduction
Nerve root metastasis of carcinoma is rare, and no cases of cervical cancer metastatic to the nerves have been reported to date. In reported nerve root metastasis of other tumors, surgical removal of the involved nerves has been performed, whereas treatment with radiotherapy was also recommended (1) (2) (3) . We herein describe the case of a patient with lumbosacral nerve root metastasis of recurrent cervical cancer. To the best of our knowledge, intensity-modulated radiation therapy (IMRT), was adopted for the first time to treat these lesions.
Case report
A 47 year-old woman was diagnosed with cervical squamous cell carcinoma in 2013 and underwent radical resection in a country hospital. The patient was confirmed to have stage IIIa disease and received one cycle of adjuvant chemotherapy; however, the details of the adjuvant treatment are not known.
The patient declined further treatment due to personal reasons. Six months later, the patient presented to our hospital with pain in her right leg, without dyskinesia. Magnetic resonance imaging (MRI) examination revealed lymph node metastasis near the right iliac blood vessels, involving the right iliac and internal obturator muscles. Subsequently, the patient was treated with 6 courses of chemotherapy with paclitaxel 210 mg and carboplatin 400 mg, every 21 days (TP regimen) and chemoradiotherapy (IMRT: Primary gross tumor volume: 55 Gy in 25 fractions; planning target volume: 45 Gy in 25 fractions; and chemotherapy: cisplatin 40 mg̸week) for local lesions. However, the pain in the right leg was not alleviated; moreover, the muscle strength decreased, and the patient was nearly unable to walk. The Visual Analog Scale (VAS) pain score was 8 to 9, the muscle strength of the right leg was level 2+, whereas it was normal in the left leg. Follow-up pelvic MRI ( Fig. 1 ) and whole-body bone scan did not reveal any metastases in the bones or muscles of the right lower limb. Subsequently, positron emission tomography̸computed tomography (PET̸CT) scan was performed (Fig. 2) , revealing sacral plexus L5̸S1 and L4̸5 nerve thickening, suggesting nerve metastases, which was the cause of the intolerable leg pain.
Oxycodone 60 mg was administered every 12 h to control the pain and a second radiotherapy was performed for the nerve root metastases. The radiation dose was planned to be 40 Gy in 22 fractions (Fig. 3) . However, after delivering 27 Gy (15 fractions), the patient discontinued radiotherapy, since there was no obvious improvement in her symptoms. One month later, the patient experienced a mild pain relief and improved muscle strength of her right leg. The VAS pain score decreased to 5 and the muscle strength increased to level 4. However, the patient finally succumbed to tumor progression 3 months after the radiotherapy.
The patient's family consented to the publication of the details and radiographic images of this case
Discussion
Cervical cancer is the second leading cause of cancer-related mortality in women. The recurrence rate for stage III disease is ≤42%. Distant recurrence is commonly reported in the following sites: Para-aortic lymph nodes (81%), lungs (21%), and supraclavicular lymph nodes (7%) (4). However, no cases on nerve root metastasis from cervical cancer have been reported to date. Even in other types of cancer, nerve root metastasis is a rare occurrence. Nerve root metastasis has been reported in renal (5), prostate (6) and lung cancer (1), and patients with nerve root metastasis have a very poor prognosis. However, due to the scarcity of such cases, there is limited experience regarding their treatment.
Since MRI is of little value in the detection of nerve root metastasis, it is very easy to miss nerve root metastasis from cancer and delay its diagnosis and treatment (3). Similar to malignant peripheral nerve sheath tumors, PET̸CT is more sensitive than MRI for detection (7) . Thus, in patients with unexplained leg pain, nerve root metastasis should be considered following exclusion of bone metastasis and PET/CT is considered a better choice.
Moreover, the choice of treatment for our patient was complicated. Surgery was employed in the majority of reported cases of nerve root metastasis from cancer (1-3). Following surgery, the pain is usually relieved, but the prognosis remains poor. Radiotherapy may also be another recommendation. The patient in our case refused to undergo surgery. In fact, since the tumor was located at a deep site and her health was poor, it is questionable whether the patient would be able to tolerate a second surgery. Considering the fact that radiotherapy is effective for advanced cervical cancer, we employed radiation treatment for this patient. As it was the second radiation, a palliative dose was administered. However, after 15 fractions of radiotherapy, the patient discontinued treatment. Of note, although the patient did not complete the entire course of radiotherapy, she benefited from this treatment: Her VAS pain score decreased from >8 to 5, while the muscle strength of the right leg increased from level 2+ to 4.
In conclusion, our experience suggests that radiotherapy may be a practical choice for nerve root metastasis from cervical cancer, particularly for patients with advanced-stage disease. 
